# Pre-Application Webinar: PAR 23-066: Research on Community Level Interventions for Firearm and Related Violence Injury and Mortality Prevention (CLIF-VP)

Dara Blachman-Demner, PhD (OBSSR)
Anna Riley, PhD (Center for Scientific Review)

**January 26, 2023** 









#### **Program Officers In Attendance**

Barbara Oudekerk, PhD  National Institute on Drug Abuse (NIDA)	Crystal Barksdale, PhD, MPH National Institute on Minority Health and Health Disparities (NIMHD)
Melissa Gerald, PhD National Institute on Aging (NIA)	Dionne Godette, PhD National Institute for Nursing Research (NINR)
Bob Freeman, PhD  National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Christopher Barnhart, PhD Sexual and Gender Minority Research Office (SGMRO)
Stephen O'Connor, PhD National Institute of Mental Health (NIMH)	Jennifer Alvidrez, PhD Office of Disease Prevention (ODP)
Lanay Mudd, PhD  National Center for Complementary and Integrative Health (NCCIH)	Lisa Begg, PhD Office of Research on Women's Health (ORWH)
Valerie Maholmes, PhD, CAS  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	



#### **Webinar Tips**

Participants will be in <u>Listening Mode</u> and will not be able to ask questions verbally or use the "Chat" function.

Participants must ask questions using the "Q and A" feature. Questions will be answered during the Q&A session at the end of the webinar as time permits.

These slides and a recording of today's webinar will be available on the OBSSR website:

https://obssr.od.nih.gov/about/violence-research-initiatives



#### **Agenda**

- I. PAR Background, Objectives, and Expectations
- II. Peer Review Process
- III. Timeline for Submission, Review, and Selection of Applications
- IV. Participant Questions



#### Part I:

# PAR Background, Objectives, and Expectations

Dara Blachman-Demner, Ph.D.

Office of Behavioral and Social Sciences Research (OBSSR)



#### **Objectives**

- To support additional research projects for the CLIF-VP research network.
- Projects will develop and test prospective interventions at the community/community organization level that aim to prevent firearm and related violence, injury and mortality.
- Projects will be funded as cooperative agreements (UG3/UH3) and will join existing projects and the Coordinating Center (U24) at the University of Michigan.



#### **Network Structure**

- Steering Committee (SC) to provide overall governance and guide crossproject activities
  - At least two representatives from each Research Project (academic PI and community PI/key personnel) and the CC and NIH science officers
  - Meet at least once a month with workgroups as needed
  - Joint activities may include: coordination of research protocols, human subjects/regulatory protocols, data harmonization and archiving, manuscript/information dissemination planning (including initial clearance of collaborative network projects).



#### **Key Definitions**

- **Community**: A specific group of people, often living in a defined geographic area, who share a common culture, values, and norms and who are arranged in a social structure according to relationships the community has developed over a period of time.
  - May be self-defined or defined by the catchment area of local government or service providers
  - Virtual or other communities that do not reside in the same geographic location are not included.
- **Community organization**: A non-Federal, non-academic organization that provides goods, services, support, resources, or advocacy to members of a defined community



#### **Background**

- Firearm-related injury and mortality is a public health condition linked to social determinants of health over the lifespan
  - From 2019 to 2020, the firearm homicide rate increased 35% to its highest recorded rate in over 25 years, exacerbating disparities
  - Pregnant women in the United States died by homicide more often than they died of pregnancy-related causes
  - In 2020:
    - Firearms accounted for the highest proportion of all methods for suicide
    - Firearm related injuries became the leading cause of death for youth ages 1-19
  - Most preventive interventions remain focused on "high-risk" individuals and/or are delivered in group settings
- There is a critical need for <u>community/community organization level</u> <u>preventive interventions</u> that engage partners in meaningful ways



#### **Potential Research Questions**

- What <u>new and innovative violence intervention practices</u> can be developed from existing theory and/or <u>basic social and behavioral research</u> that would provide additive or complementary effectiveness to existing programs and practices?
- How can the type and dose of various intervention components be <u>combined</u> and/or sequenced to optimize effectiveness and/or adoption potential in a broad range of communities to reduce violence, especially firearm violence?
- What role do the <u>unique contextual factors</u> of communities play in enhancing or inhibiting the potential effects of intervention programs?
- How do various sources of <u>adaptation</u> within a range of community contexts impact the effectiveness of the intervention on both (firearm) violence prevention and implementation outcomes?
- What are the community, organizational and <u>contextual level barriers and</u> <u>facilitators to adoption</u>, scale up, and sustainability of programs and practices and what are the best implementation strategies to address those barriers?



### Community/Community Organization (CO)-Level Interventions

- An intervention that modifies <u>community-level or community</u> organization/institution characteristics.
- This could include, but is not limited to:
  - The physical/built environment (e.g., vacant lot/abandoned building restoration)
  - The social environment (e.g., community investment in private/public spaces)
  - Policies/practices of organizations, institutions or governmental agencies that have community-level health impacts (e.g., policies to reduce the density of alcohol outlets; alternatives to incarceration)
  - Norms or collective behaviors of community residents (e.g., community surveillance efforts, bystander de-escalation strategies) or individuals within community organizations.



#### **Community/CO-Level Interventions**

- What does NOT constitute a community/CO-level intervention?
- Interventions that are delivered in community settings and/or use community-based outreach/enrollment but intervene at the individual level and do not target community/CO-level determinants of health
- An intervention that focuses exclusively on helping individuals or populations cope with the impacts of violence and do not directly address community- or organizational-level root causes of the violence
- An intervention that includes community/community organization-wide elements, but intervention effects are tested only at the individual, peer, or family level



#### Research Expectations: Required

- Led by or conducted in collaboration with appropriate community organizations.
  - Key personnel/budget/joint development of the research and intervention plan.
- Prospectively test the impact of the intervention on firearm and related violence and victimization outcomes.
- Collect data beyond individual self-report to determine how the intervention is impacting community- or organizational-level determinants.



Note: For NIMH, applications must be consistent with NIMH priorities for research on violence and aggression towards others as described in <a href="NOT-MH-22-095">NOT-MH-22-095</a>.

#### Research Expectations: Encouraged

- Multi-sectoral (e.g., education, health, criminal legal, social services)
   collaborations with public and private stakeholder organizations
  - Interventions focused solely on the health care setting are not a priority
- Guided by conceptual model identifying hypothesized pathways between the community/community organization level intervention, determinants, and violence related injury or mortality.
  - Appropriate measures and analytic methods to examine communityand organizational-level mechanisms of action and violence related outcomes.
  - Be supported by relevant preliminary data from at least one setting
  - Include assessment of relevant and intersecting social determinants of health



#### **Non-Responsive Criteria**

- Projects that do not include specific aims for both a UG3 and a UH3 phase and a welldefined set of milestones for each phase
- Projects that focus exclusively on virtual or other communities that do not reside in the same geographic location.
- Projects that do not prospectively test a community level intervention.
- Projects that do not include baseline data (i.e., prior to the implementation of the intervention) on the outcomes of interest in the populations receiving the intervention.
- Projects that use only individual-level data or are exclusively qualitative.
- Projects that do not involve one or more community partners as key personnel and/or proposed subcontracts to collaborating institutions.
- Projects that propose data collection or testing of interventions outside of the U.S.
- Projects that include prohibited policy lobbying or advocacy activities (see <a href="https://grants.nih.gov/grants/lobbying\_guidance.htm">https://grants.nih.gov/grants/lobbying\_guidance.htm</a> for more information).



#### **UG3/UH3 Phased Innovation Awards**

- Bi-phasic projects for up to five years:
  - UG3 (Phase 1):
    - One to two year award
    - Milestone-driven exploratory study to demonstrate sufficient preparation, feasibility, capacity and leveraging of foundational activities needed for the implementation studies planned in Phase 2 (UH3)
    - Includes scientific, operational and collaborative planning activities as well as tangible deliverables/preliminary findings
  - UH3 (Phase 2):
    - Three to four years of support for the implementation and evaluation of the interventions or strategies planned/developed in the UG3 phase
  - All projects are expected to be developing foundation for implementing a full-scale clinical trial in Phase 2



### UG3/UH3 Phased Innovation Awards (cont.)

- Projects that have met the milestones for the UG3 phase will be considered and prioritized for transition to the UH3 phase
  - Funding of the UG3 does not guarantee support of the UH3 award
  - All funded UG3 projects may not transition to the UH3 phase
  - Transition will be determined by the availability of funds and the outcome of a programmatic evaluation at NIH
  - Appeals of the transition decision will not be accepted



## Part II: Peer Review Process

Anna Riley, PhD
Center for Scientific Review, NIH



#### **Purpose of Peer Review**

- To see that grant applications submitted to the NIH are evaluated in a manner that is fair, independent, expert, and timely—free from inappropriate influence—so that the most promising research is funded.
- NIH uses two levels of review as mandated by statute in accordance with section 492 of the Public Health Service Act and relevant federal regulations.
  - First level is by experienced scientists/clinicians with expertise in the relevant disciplines, methodologies, and/or populations for the proposed research areas.
  - Second level is by the IC's Advisory Council, which is composed of both scientific and public representatives chosen for their expertise, interest, or activity in matters related to health and disease.
- Final funding decisions are made by IC Directors in consultation with Program Officials.



#### **Review Process**

- NIH's Center for Scientific Review (CSR) will convene a Special Emphasis Panel to review applications in response to <u>PAR-23-066</u>. Applicants do not need to provide a recommended study section assignment.
- Reviews will take place in June or July.
- All applications will receive a written critique. Only those applications deemed to have the highest scientific and technical merit will be discussed and assigned an overall impact score.
- Summary statements will be provided 30 days after the meeting completion. The Summary Statement is the official record of the review process and results. It provides a summary of key discussion points that resulted in the Final Composite Score as well as the comments and scores of assigned reviewers



#### **After Application Submission**

- APPLICANT: Submit before the deadline. Once you have submitted, ensure there are no errors that can still be corrected.
- RECEIPT BY NIH: All applications are received and processed by the Division of Receipt and Referral at the Center for Scientific Review (CSR). Each application is assessed for completeness and assigned for review, in this case to a Special Emphasis Panel run by CSR.
- PROGRAM OFFICERS: Program staff from participating ICs assess the responsiveness of applications. Non-responsive applications are withdrawn from review consideration.
- **REVIEW PROCESS**: The **Scientific Review Officer (SRO)** assembles a panel of expert reviewers to conduct the review of technical and scientific merit for the applications.



#### Confidentiality

- Review materials and proceedings of review meetings represent confidential information for reviewers and NIH staff.
- At the end of each meeting, reviewers must destroy or return all reviewrelated material.
- Reviewers should not discuss review proceedings with anyone except the SRO.
- Questions concerning review proceedings should be referred to the SRO.
- Applicants should never communicate directly with any members of the study section about an application.
- Statute of confidentiality is life long.



#### **Reviewer Conflicts of Interest (COI)**

#### What Constitutes a Reviewer COI?

- Institutional
- Family member/close friend
- Collaborator/Key Personnel
- Longstanding scientific disagreement
- Personal bias
- Appearance of conflict

http://grants.nih.gov/grants/peer/peer\_coi.htm



#### **Review Criteria**

#### **5 Scored Review Criteria**

- Significance
- Investigator(s)
- Innovation
- Approach
- Environment

#### **Overall Impact**

Assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved

Each scored from 1-9 Scored from 1-9

Reviewers will evaluate five scored review criteria (Significance, Investigators, Innovation, Approach, and Environment) in the determination of scientific merit and give an Overall Impact score on a scale of 1-9.



#### **Review Criteria**

**Significance:** Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

**Investigators:** Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

**Innovation:** Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

**Approach:** Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

**Environment:** Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?



#### PAR-23-066 Specific Review Criteria

This PAR includes unique review criteria. Please **Section V. Application Review Information** carefully.

**Significance:** Is a <u>clear and appropriate theoretical basis</u> provided for both the proposed intervention, (including the level(s) of influence addressed), as well as for the process for developing, adapting, and tailoring the intervention to the community proposed? Does the intervention have <u>potential to be sustained</u> after the project is over and/or scalable to other settings?

Investigators: Do the investigators have relevant experience developing/testing/implementing community interventions and working with the community in which the research will be conducted? Do the investigators have relevant experience with conducting multi-site or multi-project studies that require collaboration among project sites such as common protocols and data harmonization? Are the roles and responsibilities of collaborators clearly defined and appropriate? Are appropriate stakeholders, relevant to the population to be included in the research and the system/setting proposed for the project, included on the research team or on the project?

**Approach:** How well does the research project clearly identify a scientifically justifiable strategy for the UG3 phase of the project? How well does the project's conceptual framework clearly inform the analysis of data and potential pathways for the UH3 phase? How successful is the UH3 phase in proposing strategies and approaches that have a clear pathway from the UG3 data? Are the proposed Timelines and the Transition Milestone well-defined, feasible, quantifiable, and appropriate? Does the application include an adequate plan for participating in the CLIF-VP Research Network Coordinating Center, considering the CC's role to provide administrative coordination, data, measurement, and analytics support and consultation, and public/stakeholder engagement and dissemination support?



#### Additional Scorable Review Criteria in Assessing Overall Impact

These are not given individual scores but will be considered as a part of the overall impact score.

- Protections of human subjects
- Inclusion plans for sex/gender, race/ethnicity, and age of human subjects across the lifespan
- Appropriate use of vertebrate animals
- Management of biohazards



#### **Review Contact**

• If you have additional questions specifically about the review process for these applications, please contact:

Elia Ortenberg, PhD

elia.ortenberg@nih.gov

301-827-7189



#### Resources for Grant Submission or Peer Review

- Resources for using eRA Commons
  - https://era.nih.gov/sites/default/files/eRA-Commons-Resources.pdf
- Problems with Submission Processing
  - Always contact eRA Service Desk at <a href="http://grants.nih.gov/support/">http://grants.nih.gov/support/</a>
- Peer Review
  - The Center for Scientific Review (CSR) has produced several videos that provide an inside look at peer review process, on evaluating applications for scientific and technical merit and with tips for preparing applications.
  - https://era.nih.gov/era\_training/era\_videos.cfm



#### Part III:

### Timeline for Submission, Review, and Selection of Applications

Dara Blachman-Demner, PhD
Office of Behavioral and Social Sciences Research (OBSSR)



#### **Timeline**

Letter of Intent Due Date (not required):

February 17 2023

Application Due Date:

March 17 2023

Peer Review Meeting:

June 2023

Council Review:

August 2023

Start Date:

September 2023





#### **Contacts**

General/Triage: Dara Blachman-Demner, OBSSR

NICHD: Valerie Maholmes

NIA: Melissa Gerald

NIMHD: Crystal Barksdale

NINR: Dionne Godette

NCCIH: Lanay Mudd

NIAAA: Bob Freeman

• NIMH: Stephen O'Connor

• NIDA: Barbara Oudekerk

• **ODP**: Jennifer Alvidrez

SGMRO: Christopher Barnhart

• ORWH: Lisa Begg



See Financial/Grants Management contacts in the PARs.



# Part IV: Participant Questions

Submit questions via Q and A button



#### **Stay Connected!**







Office of Behavioral and Social Sciences Research

**About OBSSR:** 

https://obssr.od.nih.gov/about

**Subscribe to our Newsletter:** 

bit.ly/OBSSRUpdates